Company intelligence / Profile preview

Nocira

Tempe, Arizona, United Statesnocira.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nocira’s AVPI device is a non-invasive, drug-free neuromodulation system for acute migraine treatment. Published clinical results indicate most migraines are completely pain-free within 20 minutes of personalized treatment using the device. The AVPI platform has received FDA Breakthrough Device designation and is currently undergoing advanced clinical evaluation in multicenter, double-blind, randomized controlled trials.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device
Industry: Therapeutic Medical Devices

Partnerships

Alpha Sophia collaboration for medtech sales strategies/platform enhancements announced at LSI USA MedTech Summit in March 2024

Beyond the preview

Go deeper on Nocira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nocira.

Explore the full profile